Published in CMAJ on June 13, 2000
Canadian consensus on medically acceptable wait times for digestive health care. Can J Gastroenterol (2006) 4.34
Access to specialist gastroenterology care in Canada: the Practice Audit in Gastroenterology (PAGE) Wait Times Program. Can J Gastroenterol (2008) 1.94
Access to specialist gastroenterology care in Canada: comparison of wait times and consensus targets. Can J Gastroenterol (2008) 1.89
Approach to managing undiagnosed chest pain: could gastroesophageal reflux disease be the cause? Can Fam Physician (2007) 1.61
Kyoto global consensus report on Helicobacter pylori gastritis. Gut (2015) 1.47
Impact of reference-based pricing for histamine-2 receptor antagonists and restricted access for proton pump inhibitors in British Columbia. CMAJ (2002) 1.43
Practice Audit in Gastroenterology (PAGE) program: a novel approach to continuing professional development. Can J Gastroenterol (2006) 1.37
Treating non-ulcer dyspepsia and H pylori. BMJ (2000) 1.01
Multilaboratory comparison of proficiencies in susceptibility testing of Helicobacter pylori and correlation between agar dilution and E test methods. Antimicrob Agents Chemother (2003) 0.99
The changing pattern of upper gastro-intestinal lesions in southern Saudi Arabia: an endoscopic study. Saudi J Gastroenterol (2010) 0.95
Effectiveness and costs of implementation strategies to reduce acid suppressive drug prescriptions: a systematic review. BMC Health Serv Res (2007) 0.90
Prevalence of Helicobacter pylori in a First Nations population in northwestern Ontario. Can Fam Physician (2013) 0.88
Clinical practice: diagnosis and evaluation of dyspepsia. J Clin Gastroenterol (2010) 0.86
Approach to gastroesophageal reflux disease in primary care: Putting the Montreal definition into practice. Can Fam Physician (2008) 0.83
Changes in serum ghrelin level in relation to meal-time in patients with functional dyspepsia. United European Gastroenterol J (2015) 0.83
Diagnostic accuracy of age and alarm symptoms for upper GI malignancy in patients with dyspepsia in a GI clinic: a 7-year cross-sectional study. PLoS One (2012) 0.82
Helicobacter pylori infection and gastropathy: a comparison between Indonesian and Japanese patients. World J Gastroenterol (2009) 0.82
Counselling by primary care physicians may help patients with heartburn-predominant uninvestigated dyspepsia. Can J Gastroenterol (2010) 0.82
Lafutidine 10 mg versus Rabeprazole 20 mg in the Treatment of Patients with Heartburn-Dominant Uninvestigated Dyspepsia: A Randomized, Multicentric Trial. Gastroenterol Res Pract (2011) 0.80
Treatment of Functional Dyspepsia. Curr Treat Options Gastroenterol (2004) 0.80
Functional dyspepsia and nonerosive reflux disease: clinical interactions and their implications. MedGenMed (2007) 0.80
Cost-effectiveness of the carbon-13 urea breath test for the detection of Helicobacter pylori: an economic analysis. Ont Health Technol Assess Ser (2013) 0.80
Maintenance treatment of gastroesophageal reflux disease: an evaluation of continuous and on-demand therapy with rabeprazole 20 mg. Can J Gastroenterol (2007) 0.78
Helicobacter pylori Eradication Therapy in Nonulcer Dyspepsia is Beneficial. Saudi J Gastroenterol (2008) 0.78
On the association between soft drink consumption and Helicobacter pylori infection. Dig Dis Sci (2011) 0.78
Dyspepsia, peptic ulcer disease, and esophageal reflux disease. West J Med (2002) 0.78
Carbon-13 urea breath test for Helicobacter pylori infection in patients with uninvestigated ulcer-like dyspepsia: an evidence-based analysis. Ont Health Technol Assess Ser (2013) 0.77
Helicobacter pylori related dyspepsia: prevalence and treatment outcomes at University Kebangsaan Malaysia-Primary Care Centre. Asia Pac Fam Med (2009) 0.77
Does the evidence show that prokinetic agents are effective in healing esophagitis and improving symptoms of GERD? Open Med (2007) 0.76
Is Endoscopy Really Necessary in My Case? A Four Year Retrospective Study. J Clin Diagn Res (2015) 0.75
Managing uninvestigated dyspepsia in primary care. BMJ (2008) 0.75
Update from the Canadian Dyspepsia Working Group. CMAJ (2000) 0.75
AAPS/RAPS/CAPRA collaborative program: exploring the challenges of drug regulation in a global environment: clinical concerns. AAPS PharmSci (2003) 0.75
Management of patients with uninvestigated dyspepsia. CMAJ (2001) 0.75
Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med (1991) 10.55
Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet (1994) 6.40
Report of the Canadian Hypertension Society Consensus Conference: 1. Introduction. CMAJ (1993) 6.20
Validation of a rapid whole blood test for diagnosing Helicobacter pylori infection. BMJ (1997) 5.80
COX-2 inhibitors. Lancet (1999) 5.49
Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials. Lancet (1996) 5.03
Prospective screening of dyspeptic patients by Helicobacter pylori serology. Lancet (1995) 5.02
Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia. N Engl J Med (1998) 4.99
Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterology (1992) 4.84
Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group. N Engl J Med (1998) 4.66
Early detection of gastric cancer. BMJ (1990) 4.26
Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA (1999) 4.25
Gastric cancer: a curable disease in Britain. BMJ (1993) 4.24
Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med (1998) 4.24
Studies of the epidemiology of peptic ulcer in a rural community: prevalence and natural history of dyspepsia and peptic ulcer. Gut (1968) 4.21
A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. Gastroenterology (1999) 4.13
Symptoms in gastro-oesophageal reflux disease. Lancet (1990) 4.10
A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med (1998) 3.96
Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. Gastroenterology (1995) 3.86
Empirical H2-blocker therapy or prompt endoscopy in management of dyspepsia. Lancet (1994) 3.84
Challenges in managing dyspepsia in general practice. BMJ (1997) 3.78
Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA (1999) 3.60
Factors affecting the decision to consult with dyspepsia: comparison of consulters and non-consulters. J R Coll Gen Pract (1989) 3.53
An evidence-based appraisal of reflux disease management--the Genval Workshop Report. Gut (1999) 3.45
Management of dyspepsia: report of a working party. Lancet (1988) 3.08
The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. Scand J Gastroenterol (1998) 3.04
Initial endoscopy or empirical therapy with or without testing for Helicobacter pylori for dyspepsia: a decision analysis. Gastroenterology (1996) 3.00
Lack of discriminant value of dyspepsia subgroups in patients referred for upper endoscopy. Gastroenterology (1993) 2.99
Does concern about missing malignancy justify endoscopy in uncomplicated dyspepsia in patients aged less than 55? Am J Gastroenterol (1999) 2.89
Helicobacter pylori: new developments and treatments. CMAJ (1997) 2.77
Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Misoprostol Study Group. Ann Intern Med (1993) 2.74
Dyspepsia in England and Scotland. Gut (1990) 2.73
Drug treatment of functional dyspepsia: a systematic analysis of trial methodology with recommendations for design of future trials. Am J Gastroenterol (1996) 2.73
Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomarkers Prev (1997) 2.68
Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology (1997) 2.67
Do young patients with dyspepsia need investigation? Lancet (1988) 2.65
Diagnostic tests for Helicobacter pylori: a prospective evaluation of their accuracy, without selecting a single test as the gold standard. Am J Gastroenterol (1996) 2.65
Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology (1997) 2.64
Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet (2000) 2.63
Is Helicobacter pylori associated with non-ulcer dyspepsia and will eradication improve symptoms? A meta-analysis. BMJ (1999) 2.58
Onset and disappearance of gastrointestinal symptoms and functional gastrointestinal disorders. Am J Epidemiol (1992) 2.54
Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine. BMJ (1988) 2.48
Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies). Aliment Pharmacol Ther (1998) 2.45
Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol (1998) 2.44
Heartburn treatment in primary care: randomised, double blind study for 8 weeks. BMJ (1999) 2.44
Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study. BMJ (1997) 2.39
Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med (1996) 2.37
Eradication of Helicobacter pylori affects symptoms in non-ulcer dyspepsia. Scand J Gastroenterol (1997) 2.32
Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic multicentre study. Scand J Gastroenterol (1996) 2.30
Increasing prevalence of Helicobacter pylori infection with age: continuous risk of infection in adults rather than cohort effect. J Infect Dis (1994) 2.26
Diagnostic tests for Helicobacter pylori--can they help select patients for endoscopy? N Z Med J (1996) 2.25
Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia. N Engl J Med (1999) 2.15
Importance of childhood socioeconomic status on the current prevalence of Helicobacter pylori infection. Gut (1994) 2.14
Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol (1997) 2.02
Cisapride and fatal arrhythmia. N Engl J Med (1996) 2.00
Double-contrast barium meal and upper gastrointestinal endoscopy. A comparative study. Ann Intern Med (1984) 1.90
A survey of dyspepsia in Great Britain. Aliment Pharmacol Ther (1996) 1.79
Absence of therapeutic benefit from antacids or cimetidine in non-ulcer dyspepsia. N Engl J Med (1986) 1.79
Helicobacter pylori infection as a cause of gastritis, duodenal ulcer, gastric cancer and nonulcer dyspepsia: a systematic overview. CMAJ (1994) 1.78
Rationale and efficacy of conservative therapy for gastroesophageal reflux disease. Arch Intern Med (1991) 1.77
Quality of life in patients with upper gastrointestinal symptoms. An improved evaluation of treatment regimens? Scand J Gastroenterol (1993) 1.75
What role does Helicobacter pylori play in dyspepsia and nonulcer dyspepsia? Arguments for and against H. pylori being associated with dyspeptic symptoms. Gastroenterology (1997) 1.72
Appropriateness of indications for diagnostic upper gastrointestinal endoscopy: association with relevant endoscopic disease. Gastrointest Endosc (1995) 1.66
Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride. Aliment Pharmacol Ther (1997) 1.63
Can the age limit for endoscopy be increased in dyspepsia patients who do not have alarm symptoms? Am J Gastroenterol (1999) 1.60
Gastroduodenitis. A broader concept of peptic ulcer disease. Dig Dis Sci (1980) 1.59
Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration. Gastroenterology (1997) 1.59
Nizatidine prevents peptic ulceration in high-risk patients taking nonsteroidal anti-inflammatory drugs. Arch Intern Med (1993) 1.58
Geographical differences in the prevalence of dyspepsia. Scand J Gastroenterol Suppl (1991) 1.57
Prevalence and impact of upper gastrointestinal symptoms in the Canadian population: findings from the DIGEST study. Domestic/International Gastroenterology Surveillance Study. Am J Gastroenterol (1999) 1.54
Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol (1997) 1.52
Treatment of peptic ulcers caused by Helicobacter pylori. N Engl J Med (1993) 1.52
Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastro-intestinal ulcer models in rats. Br J Pharmacol (1998) 1.44
Canadian Helicobacter pylori Consensus Conference update: infections in adults. Canadian Helicobacter Study Group. Can J Gastroenterol (1999) 1.43
The predictive value of history in dyspepsia. Scand J Gastroenterol (1990) 1.42
Etiology of dyspepsia: four hundred unselected consecutive patients in general practice. Scand J Gastroenterol (1995) 1.41
Guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Practice Parameters Committee of the American College of Gastroenterology. Arch Intern Med (1995) 1.39
Do commercial serological kits for Helicobacter pylori infection differ in accuracy? A meta-analysis. Am J Gastroenterol (1996) 1.38
Effects of sleeping with the bed-head raised and of ranitidine in patients with severe peptic oesophagitis. Lancet (1987) 1.35
A simple, rapid, and highly reliable capsule-based 14C urea breath test for diagnosis of Helicobacter pylori infection. Scand J Gastroenterol (1995) 1.33
A Canadian physician survey of dyspepsia management. Can J Gastroenterol (1998) 1.30
Helicobacter pylori infection and dyspepsia. Scand J Gastroenterol Suppl (1996) 1.29
Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity? Ann Intern Med (2000) 1.27
Definitions of dyspepsia. Scand J Gastroenterol Suppl (1991) 1.26
Dyspepsia in the community: a follow-up study. Br J Clin Pract (1992) 1.25
Gastro-oesophageal reflux disease. Digestion (1998) 1.24
Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen. Aliment Pharmacol Ther (1999) 1.24
Does endoscopy have a positive impact on quality of life in dyspepsia? Gastrointest Endosc (1998) 1.24
What is behind dyspepsia? Dig Dis Sci (1993) 1.23
Evaluation of elevation of the head of the bed, bethanechol, and antacid form tablets on gastroesophageal reflux. Dig Dis Sci (1981) 1.22
Canadian Helicobacter pylori consensus conference. Canadian Association of Gastroenterology. Can J Gastroenterol (1998) 1.19
First line treatment with omeprazole provides an effective and superior alternative strategy in the management of dyspepsia compared to antacid/alginate liquid: a multicentre study in general practice. Aliment Pharmacol Ther (1998) 1.15
The role of Helicobacter pylori in pathogenesis: the spectrum of clinical outcomes. Scand J Gastroenterol Suppl (1996) 1.13
Lansoprazole 30 mg daily versus ranitidine 150 mg b.d. in the treatment of acid-related dyspepsia in general practice. Aliment Pharmacol Ther (1997) 1.13
Importance of reflux symptoms in functional dyspepsia. Gut (1995) 1.12
Gastroesophageal reflux in obese patients is not reduced by weight reduction. Scand J Gastroenterol (1996) 1.11
Misoprostol and ranitidine in the prevention of NSAID-induced ulcers: a prospective, double-blind, multicenter study. Am J Gastroenterol (1996) 1.10
Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users. Aliment Pharmacol Ther (1998) 1.07
Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut (1999) 7.14
Mycobacterium avium complex infections in patients with the acquired immunodeficiency syndrome. Ann Intern Med (1986) 6.79
Effect of a general practitioner's consulting style on patients' satisfaction: a controlled study. BMJ (1990) 6.15
Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ (2000) 6.10
Infections caused by Mycobacterium avium complex in immunocompromised patients: diagnosis by blood culture and fecal examination, antimicrobial susceptibility tests, and morphological and seroagglutination characteristics. J Clin Microbiol (1985) 5.22
Referral to hospital: perceptions of patients, general practitioners and consultants about necessity and suitability of referral. Fam Pract (1987) 5.11
Mutation of the Angelman ubiquitin ligase in mice causes increased cytoplasmic p53 and deficits of contextual learning and long-term potentiation. Neuron (1998) 4.92
Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis. Lancet (2001) 4.60
Comparison of criteria derived by government and patients for evaluating general practitioner services. BMJ (1989) 4.36
Fungemia in the immunocompromised host. Changing patterns, antigenemia, high mortality. Am J Med (1981) 4.31
Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med (1998) 4.24
Treatment of infections in patients with the acquired immunodeficiency syndrome. Ann Intern Med (1985) 4.02
Fungemia in a cancer hospital: changing frequency, earlier onset, and results of therapy. Rev Infect Dis (1985) 4.00
Aspergillosis complicating neoplastic disease. Am J Med (1973) 3.80
Diagnostic criteria for Walker-Warburg syndrome. Am J Med Genet (1989) 3.74
Implementing evidence based medicine in general practice: audit and qualitative study of antithrombotic treatment for atrial fibrillation. BMJ (1999) 3.62
A randomised controlled trial of abdominal versus laparoscopic sacrocolpopexy for the treatment of post-hysterectomy vaginal vault prolapse: LAS study. Int Urogynecol J (2012) 3.36
Imprinted expression of the murine Angelman syndrome gene, Ube3a, in hippocampal and Purkinje neurons. Nat Genet (1997) 3.32
Human immunity to Pseudomonas aeruginosa. I. In-vitro interaction of bacteria, polymorphonuclear leukocytes, and serum factors. J Infect Dis (1972) 3.28
Megestrol acetate in patients with AIDS-related cachexia. Ann Intern Med (1994) 3.25
Continuous high-grade mycobacterium avium-intracellulare bacteremia in patients with the acquired immune deficiency syndrome. Am J Med (1985) 3.19
Reasons for referral to hospital: extent of agreement between the perceptions of patients, general practitioners and consultants. Fam Pract (1986) 3.14
Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study. Helicobacter (1996) 3.13
Chlamydia pneumoniae IgA titres and coronary heart disease; prospective study and meta-analysis. Eur Heart J (2002) 3.09
Comparative recovery of bacteria and yeasts from lysis-centrifugation and a conventional blood culture system. J Clin Microbiol (1983) 3.09
Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother (1997) 3.06
A reevaluation of cancer incidence near the Three Mile Island nuclear plant: the collision of evidence and assumptions. Environ Health Perspect (1997) 3.04
Investigation of burnout in a sample of British general practitioners. Br J Gen Pract (1995) 3.03
Mortality in severe meningococcal disease. Arch Dis Child (2001) 3.03
Intraorbital wood. Detection by magnetic resonance imaging. Ophthalmology (1990) 2.99
Bacteremia and fungemia complicating neoplastic disease. A study of 364 cases. Am J Med (1977) 2.92
Measuring general practitioner referrals: patient, workload and list size effects. J R Coll Gen Pract (1988) 2.91
The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: the Canadian Adult Dyspepsia Empiric Treatment - Prompt Endoscopy (CADET-PE) study. Aliment Pharmacol Ther (2003) 2.83
Bronchoalveolar lavage in the diagnosis of diffuse pulmonary infiltrates in the immunosuppressed host. Ann Intern Med (1984) 2.80
Measuring postoperative complications in general surgery patients using an outcomes-based strategy: comparison with complications presented at morbidity and mortality rounds. Surgery (1997) 2.76
Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis. Pediatr Pulmonol (1999) 2.73
Species identification of coagulase-negative staphylococcal isolates from blood cultures. J Clin Microbiol (1982) 2.71
For the price of a pen! N Z Med J (1990) 2.67
von Willebrand factor and coronary heart disease: prospective study and meta-analysis. Eur Heart J (2002) 2.66
Preferences of healthy and ill patients for style of general practitioner care: implications for workload and financial incentives under the new contract. Br J Gen Pract (1991) 2.66
Telephone consultations in general practice: an additional or alternative service? Br J Gen Pract (1995) 2.62
Tobramycin (nebramycin factor 6): in vitro activity against Pseudomonas aeruginosa. Appl Microbiol (1971) 2.60
Chlamydia pneumoniae IgG titres and coronary heart disease: prospective study and meta-analysis. BMJ (2000) 2.56
Septicemia due to Aeromonas hydrophila: clinical and immunologic aspects. J Infect Dis (1973) 2.55
Oxidative damage to DNA in diabetes mellitus. Lancet (1996) 2.54
Serologic responses to Pneumocystis carinii antigens in health and disease. J Infect Dis (1990) 2.51
Patients' views of priority setting in health care: an interview survey in one practice. BMJ (1995) 2.50
Patients' responses to risk information about the benefits of treating hypertension. Br J Gen Pract (2001) 2.50
Association of respiratory syncytial virus bronchiolitis with the interleukin 8 gene region in UK families. Thorax (2000) 2.49
Voltage-activated calcium channels that must be phosphorylated to respond to membrane depolarization. Proc Natl Acad Sci U S A (1987) 2.48
Effects by heme, insulin, and serum albumin on heme and protein synthesis in chick embryo liver cells cultured in a chemically defined medium, and a spectrofluorometric assay for porphyrin composition. J Biol Chem (1975) 2.47
Association of amino acid substitutions in penicillin-binding protein 3 with beta-lactam resistance in beta-lactamase-negative ampicillin-resistant Haemophilus influenzae. Antimicrob Agents Chemother (2001) 2.46
Fibrin D-dimer and coronary heart disease: prospective study and meta-analysis. Circulation (2001) 2.43
Opportunistic infection in previously healthy women. Initial manifestations of a community-acquired cellular immunodeficiency. Ann Intern Med (1982) 2.41
From the Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis (1990) 2.39
Tuberculosis complicating neoplastic disease. A review of 201 cases. Cancer (1974) 2.36
Pneumothorax in AIDS. Ann Intern Med (1991) 2.29
Characterization of response elements for androgens, glucocorticoids and progestins in mouse mammary tumour virus. Nucleic Acids Res (1988) 2.28
Candidiasis: detection by gas-liquid chromatography of D-arabinitol, a fungal metabolite, in human serum. Science (1979) 2.26
Quality of Life in Reflux and Dyspepsia patients. Psychometric documentation of a new disease-specific questionnaire (QOLRAD). Eur J Surg Suppl (1998) 2.26
Protection of cattle from bovine tuberculosis by vaccination with BCG by the respiratory or subcutaneous route, but not by vaccination with killed Mycobacterium vaccae. Res Vet Sci (1995) 2.25
Nocardia asteroides infection complicating neoplastic disease. Am J Med (1971) 2.23
Aspirin use in middle-aged men with cardiovascular disease: are opportunities being missed? Br J Gen Pract (1997) 2.22
Infectious morbidity associated with long-term use of venous access devices in patients with cancer. Ann Intern Med (1993) 2.22
The prevalence of yeasts in clinical specimens from cancer patients. Am J Clin Pathol (1980) 2.19
Functional conservation of atonal and Math1 in the CNS and PNS. Development (2000) 2.18
Phycomycosis complicating leukemia and lymphoma. Ann Intern Med (1972) 2.17
Increased arabinitol levels in experimental candidiasis in rats: arabinitol appearance rates, arabinitol/creatinine ratios, and severity of infection. J Infect Dis (1982) 2.16
Nude mouse: a new experimental model for Pneumocystis carinii infection. Science (1977) 2.16
1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin Infect Dis (1997) 2.14
Multiorgan autonomic dysfunction in mice lacking the beta2 and the beta4 subunits of neuronal nicotinic acetylcholine receptors. J Neurosci (1999) 2.12
Clinical spectrum of infection due to Bacillus species. Am J Med (1973) 2.11
Complement-fixation tests with cell lines derived from Burkitt's lymphoma and acute leukemias. J Bacteriol (1966) 2.10
Comparative recovery of fungi from biphasic and conventional blood culture media. J Clin Microbiol (1981) 2.09
Invasive aspergillosis. Progress in early diagnosis and treatment. Am J Med (1981) 2.07
In vitro activity of the new semi-synthetic polypeptide cilofungin (LY121019) against Aspergillus and Candida species. Eur J Clin Microbiol Infect Dis (1990) 2.06
Patterns of work in general practice in the Bromley health district. J R Coll Gen Pract (1987) 2.05
Putting patient care first when group practices break down. Med J Aust (1998) 2.04
PCV-2 genotype definition and nomenclature. Vet Rec (2008) 2.04
Mycobacterium haemophilum: microbiology and expanding clinical and geographic spectra of disease in humans. Clin Microbiol Rev (1996) 2.04
Geographic density of landfill sites and risk of congenital anomalies in England. Occup Environ Med (2008) 2.00
Guidelines for reporting clinical features in cases with MECP2 mutations. Brain Dev (2001) 1.99
Bacterial pneumonia in patients with the acquired immunodeficiency syndrome. Ann Intern Med (1986) 1.99
The patient's view. Soc Sci Med (1984) 1.97
Detection of HIV-1 DNA sequences in pre-ejaculatory fluid. Lancet (1992) 1.93
Vancomycin-resistant Enterococcus faecium on a pediatric oncology ward: duration of stool shedding and incidence of clinical infection. Pediatr Infect Dis J (1996) 1.93
Cryptosporidium and cryptosporidiosis. Rev Infect Dis (1987) 1.91
The T cell chemoattractant IFN-inducible protein 10 is essential in host defense against viral-induced neurologic disease. J Immunol (2000) 1.91
Access to specialist gastroenterology care in Canada: comparison of wait times and consensus targets. Can J Gastroenterol (2008) 1.89
What do patients want? BMJ (1991) 1.85
Tuberculosis in the AIDS era. Clin Microbiol Rev (1995) 1.85
Toxoplasma gondii serology in HIV-infected patients: the development of central nervous system toxoplasmosis in AIDS. AIDS (1990) 1.82
Immunodiffusion and agglutination tests for Candida in patients with neoplastic disease: inconsistent correlation of results with invasive infections. J Infect Dis (1977) 1.82
Megacystis, mydriasis, and ion channel defect in mice lacking the alpha3 neuronal nicotinic acetylcholine receptor. Proc Natl Acad Sci U S A (1999) 1.81
TBARS and cardiovascular disease in a population-based sample. J Cardiovasc Risk (2001) 1.81
Female streetworker--prostitutes in Glasgow: a descriptive study of their lifestyle. AIDS Care (1993) 1.80